| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 12, 2025 3:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $10 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. The securities were offered and sold pursuant to
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in a best-efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine*, for general corporate
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
S-8 - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
424B5 - CEL SCI CORP (0000725363) (Filer)
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)